CRTX — CRISM' Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- £4.41m
- £1.02m
Annual cashflow statement for CRISM' Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | — | — | — | — | 0.365 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1.9 | -2.2 | -1.83 | -3.36 | -2.77 |
| Capital Expenditures | -0.501 | -0.564 | -0.426 | -0.327 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.001 | -4.62 | 6.46 | 0.141 | 34.9 |
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.5 | -5.18 | 6.04 | -0.186 | 34.9 |
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.5 | 9.89 | 0 | 0.345 | -31.4 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.859 | 2.39 | 3.89 | -3.2 | 0.76 |